Cargando…
c-Src Binds to the Cancer Drug Ruxolitinib with an Active Conformation
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase. There is no structural information of Ruxolitinib binding to an...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157781/ https://www.ncbi.nlm.nih.gov/pubmed/25197973 http://dx.doi.org/10.1371/journal.pone.0106225 |